Lubiprostone protects esophageal mucosa from acid injury in porcine esophagus
Krüger, L., Pridgen, T. A., Taylor, E. R., Garman, K. S., & Blikslager, A. T. (2020, February 18). American Journal of Physiology-Gastrointestinal and Liver Physiology, Vol. 318, pp. G613–G623.
author keywords: ClC-2; esophagus; injury; lubiprostone; repair
MeSH headings : 16,16-Dimethylprostaglandin E2 / pharmacology; Animals; Bumetanide / pharmacology; Chloride Channel Agonists / pharmacology; Chloride Channels / genetics; Chloride Channels / metabolism; Chlorides / pharmacology; Cystic Fibrosis Transmembrane Conductance Regulator / genetics; Cystic Fibrosis Transmembrane Conductance Regulator / metabolism; Dose-Response Relationship, Drug; Esophageal Mucosa / drug effects; Female; Gene Expression Regulation / drug effects; Hydrochloric Acid / pharmacology; Lubiprostone / pharmacology; Male; Occludin / metabolism; Swine; Time Factors; Zinc Compounds / pharmacology
topics (OpenAlex): Gastroesophageal reflux and treatments; Esophageal and GI Pathology; Helicobacter pylori-related gastroenterology studies
TL;DR:
It is concluded that ClC-2 contributes to esophageal protection from acid exposure, potentially offering a new therapeutic target.
(via
Semantic Scholar)
UN Sustainable Development Goal Categories
Sources: Web Of Science, NC State University Libraries